Arachidonic Acid

Arachidonic Acid

SCHEMBL607755

CCCCCC=CCC=CCC=CC/C=C\CCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 1.00
PPARD Q03181 6/20 1.00
PPARA Q07869 6/20 1.00
ALDH1A1 P00352 5/20 1.00
FABP4 P15090 4/20 1.00
HSD17B10 Q99714 4/20 1.00
LMNA P02545 3/20 1.00
CYP19A1 P11511 3/20 1.00
ALOX15 P16050 3/20 1.00
NR4A2 P43354 3/20 1.00
MAPT P10636 3/20 1.00
BLM P54132 3/20 1.00
L3MBTL1 Q9Y468 2/20 1.00
KDM4E B2RXH2 2/20 1.00
CYP3A4 P08684 2/20 1.00
HPGD P15428 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
AKR1C3 P42330 2/20 1.00
USP2 O75604 2/20 1.00
RECQL P46063 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7875988 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL18185463 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
SCHEMBL7875990 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
SCHEMBL17540736 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
SCHEMBL542242 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
SCHEMBL13033028 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL25417373 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL18185503 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL20656587 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4
Arachidonic Acid SCHEMBL3064936 1.00 PPARG (1.00) PPARGPPARDPPARAALDH1A1FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024168236-A2 METHODS FOR DETECTING AND TREATING CAVERNOUS ANGIOMA THE UNIVERSITY OF CHICAGO (US) 2024-08-15 WO claimed
EP-3383380-B1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2023-01-04 EP claimed
CN-114806022-A Positively charged biological filler and preparation method thereof 中国科学院青岛生物能源与过程研究所 2022-07-29 CN claimed
CN-112996500-A Compositions and methods for modulating ELOVL2 优美佳生物技术有限公司 2021-06-18 CN claimed
US-20150209441-A1 Anandamide-Modified Nucleic Acid Molecules BASECLICK GMBH (DE) 2015-07-30 US claimed
CN-104540525-A Anandamide-modified nucleic acid molecules BASECLICK GMBH 2015-04-22 CN claimed
EP-1854462-A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids DSMIP Assets B.V. (NL) 2007-11-14 EP claimed
EP-1852115-A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids DSM IP Assets B.V. (NL) 2007-11-07 EP claimed
EP-1370257-B1 COMPOSITION FOR THE PREVENTION OF OSTEOPOROSIS consisting of A COMBINATION OF ISOFLAVONES AND POLYUNSATURATED FATTY ACIDS DSM IP ASSETS BV (NL) 2007-07-25 EP claimed
JP-1019018-A None JP disclosed
EP-4733373-A1 METHOD FOR PRODUCING HIGHLY UNSATURATED FATTY ACID ESTER COMPOSITION Nissui Corporation (JP) 2026-04-29 EP disclosed
EP-3817810-B1 MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3- D]PYRIMIDINE COMPOUND AND USE THEREOF PFIZER (US) 2025-09-17 EP disclosed
US-20250282789-A1 CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF PFIZER INC. (US) 2025-09-11 US disclosed
US-12410172-B2 Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof PFIZER INC. (US) 2025-09-09 US disclosed
EP-0749468-A1 REFINING OIL COMPOSITIONS NORSK HYDRO a.s. (NO) 1996-12-27 EP disclosed
EP-0449436-B1 Method of separating sesamin analogues TAKEMOTO OIL & FAT CO LTD (JP) 1996-08-14 EP disclosed
WO-1995024459-A1 REFINING OIL COMPOSITIONS NORSK HYDRO A.S (NO) 1995-09-14 WO disclosed
US-5209826-A Method of separating sesamin and episesamin TAKEMOTO YUSHI KABUSHIKI KAISHA (JP) 1993-05-11 US disclosed
EP-0449436-A1 Method of separating sesamin analogues Takemoto Yushi Kabushiki Kaisha (JP) 1991-10-02 EP disclosed
JP-S6419018-A CHOLESTEROL DEPRESSING AGENT NIPPON OILS & FATS CO LTD 1989-01-23 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282789-A1 CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE COMPOUND AND USE THEREOF PDXK, OR10J3, CYP2J2 PPARG 643/4885PPARD 207/4885PPARA 240/4885
US-12410172-B2 Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof CYP4B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CALU PPARG 1333/4885PPARD 831/4885PPARA 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.